Shire Pharmaceuticals Posts in-Line Q4; Sees Profit Growth in 2011

LONDON, Feb 10 (Reuters) - Shire (SHP.L) posted earnings in line with market expectations, helped by its hyperactivity drug Vyvanse and the windfall it is continuing to reap in rare diseases from production problems at rival Genzyme (GENZ.O).